Mon, Jul 28, 2014, 5:17 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Oncothyreon Inc Message Board

  • jyardagg jyardagg Apr 24, 2013 1:10 PM Flag

    dichotomy of a negative cycle

    when they use your stock as the poster child example of a failed trial.
    ... but also, at same time, fail to see the coming rising.
    px 866 has some promise.
    I recall when nobody knew about ONxx's nexavar after their novel O15 failed.
    nexavar and px 866 Pi3K inhibitor are both small molecule compounds.
    hope to see a ONTY rising someday through and past this negative cycle.

    thank you.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • another thing is that often in a negative phase the issue starts to turn around slowly while negative sentiment is at its peak. In other words the negativity gets too frothy. look at the banks when bac was near $2 a share and then slowly started climbing back while negative sentiment lingered. hen just one catalyst acts like gunpowder to fuel a return to share levels. PX 866 could reflect the coming rising/ like no other issue out there if it inhibits the pathway to all tumor growth in multiple forms of cancer.

      insert the boss's song here. come on up to rising .... come on uppp

      thank you.

2.87-0.14(-4.65%)Jul 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.